<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-C
REPORT BY ISSUER OF SECURITIES QUOTED ON NASDAQ
INTERDEALER QUOTATION SYSTEM
Filed pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934 and Rule 13a-17
or 15d-17 thereunder
Medicis Pharmaceutical Corporation
----------------------------------------------
(Exact name of issuer as specified in charter)
4343 East Camelback Road, Suite 250, Phoenix, Arizona 85018
-----------------------------------------------------------
(Address of principal executive offices)
Issuer's telephone number, including area code (602) 808-8800
---------------
I. CHANGE IN NUMBER OF SHARES OUTSTANDING
Indicate any change (increase or decrease) of 5% or more in the number of shares
outstanding:
1. Title of security: Class A Common, Class B Common and Series B Preferred
2. Number of shares
outstanding before
the change: 4,555,290 shares of Class A Common Stock and 125,322
shares of Class B Common Stock
3. Number of shares
outstanding after
the change: 6,832,935 shares of Class A Common Stock, 125,322
shares of Class B Common Stock and 62,660 shares of
Series B Preferred Stock
4. Effective date
of change: August 2, 1996
5. Method of change: A 3-for-2 forward stock split effected in the form of
a 50% stock dividend Specify method (such as merger,
acquisition, exchange, distribution, stock split,
reverse split, acquisition of stock for treasury, etc.)
Give brief description of transaction: Holders of Class A Common Stock received
one additional share of Class A Common Stock for every two shares of Class A
Common Stock held by such holder and holders of Class B shares receive one share
of Series B Preferred Stock for every two shares of Class B Common Stock held by
such holder. The Series B Preferred Stock have rights, preferences and
privileges that are identical to the Class B Common Stock, except that they are
automatically convertible into the same number of shares of Class B Common Stock
upon an amendment to the Company's Certificate of Incorporation creating a
number of shares of Class B Common Stock which is sufficient to effect such
conversion.
II. CHANGE IN NAME OF ISSUER
1. Name prior to change:_____________________________________________________
2. Name after change:________________________________________________________
3. Effective date of charter amendment changing name:________________________
4. Date of shareholder approval of change, if required:______________________
MEDICIS PHARMACEUTICAL CORPORATION
DATE: August 8, 1996 By: /s/ Mark A. Prygocki, Sr.
---------------------------------
Mark A. Prygocki, Sr.
Its: Chief Financial Officer
